Envista (NVST) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
16 Apr, 2026Executive summary
Achieved double-digit core sales, adjusted EBITDA, and EPS growth in Q4 2025, with all major businesses and geographies contributing positively and 6.5% core growth for the year.
Launched several new products in 2025, generating approximately $100 million in revenue, and increased customer training by 30%.
Implemented a $250 million share repurchase program, returning $166 million to shareholders in 2025 (over 9 million shares repurchased at ~$18/share).
Advanced the Value Creation Plan with record employee engagement, significant management refresh, and increased internal promotions.
Donated over $2 million to community organizations through the Envista Smile Project.
Financial highlights
Q4 2025 sales reached $751 million, with core sales up 10.8% year-over-year; adjusted EBITDA was $111 million (14.8% margin, up 90 bps), and adjusted EPS was $0.38, up 58% year-over-year.
Full-year 2025 sales were $2,719 million, with core sales up 6.5%; adjusted EBITDA was $372 million (13.7% margin, up 190 bps), and adjusted EPS was $1.19, up 63% year-over-year.
Free cash flow for 2025 was $231 million, with a conversion rate of 114%.
Q4 adjusted gross margin was 55%, down 220 basis points year-over-year; full-year adjusted gross margin was 55.1%, down 30 basis points.
Net debt to adjusted EBITDA at approximately 0.6x, indicating a strong balance sheet.
Outlook and guidance
2026 guidance: core revenue growth of 2%-4%, adjusted EBITDA growth of 7%-13%, adjusted EPS of $1.35–$1.45 (13%-22% growth), and free cash flow conversion around 100%.
Dental market expected to remain stable with potential modest improvement; FX projected to provide a 1.5% revenue benefit.
Tariff headwinds expected to increase to $40 million in 2026, but anticipated to be offset by price increases and cost reductions.
Non-GAAP tax rate expected to decrease to approximately 28% in 2026, with actions taken to reduce tax rate by ~4 points.
Guidance does not reflect future gains/losses from unpredictable events such as acquisitions, divestitures, or legal matters.
Latest events from Envista
- Q1 2026 saw 9.5% core growth, margin expansion, and a $300M share repurchase authorization.NVST
Q1 20267 May 2026 - Key votes include director elections, auditor ratification, and executive pay approval.NVST
Proxy filing7 Apr 2026 - Annual meeting to vote on directors, auditor, executive pay, and ESG priorities.NVST
Proxy filing7 Apr 2026 - Targets 2%-4% core growth and 7%-10% EPS growth, driven by innovation and operational discipline.NVST
CMD 20253 Feb 2026 - Q2 loss of $1.15B on impairments; sales, margins fell, but cash flow and Q4 outlook improved.NVST
Q2 20242 Feb 2026 - Q3 2024 sales fell 5.3%, net income dropped, but full-year guidance was reaffirmed.NVST
Q3 202417 Jan 2026 - Dental market growth, innovation, and operational execution drive double-digit financial gains.NVST
44th Annual J.P. Morgan Healthcare Conference13 Jan 2026 - Stable dental market, growth investments, and China VBP shape outlook for 2025.NVST
7th Annual Evercore ISI HealthCONx Conference12 Jan 2026 - Strategic investments and stable market trends position the business for renewed growth.NVST
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026